Royalty Pharma plc (NASDAQ:RPRX) Given Average Rating of "Buy" by Analysts

Shares of Royalty Pharma plc (NASDAQ:RPRX - Get Free Report) have been given a consensus recommendation of "Buy" by the five brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $42.50.

A number of brokerages have recently commented on RPRX. TD Cowen raised Royalty Pharma to a "strong-buy" rating in a report on Tuesday, December 24th. Citigroup reissued a "buy" rating on shares of Royalty Pharma in a research report on Friday, March 28th.

Royalty Pharma Trading Down 1.3 %

NASDAQ:RPRX opened at $32.19 on Tuesday. The company has a market capitalization of $18.56 billion, a P/E ratio of 22.20, a P/E/G ratio of 2.31 and a beta of 0.50. The stock's 50 day moving average price is $32.56 and its 200 day moving average price is $29.32. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44. Royalty Pharma has a 52 week low of $24.05 and a 52 week high of $34.20.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, beating analysts' consensus estimates of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. On average, research analysts forecast that Royalty Pharma will post 4.49 EPS for the current fiscal year.

Hedge Funds Weigh In On Royalty Pharma

Institutional investors and hedge funds have recently bought and sold shares of the stock. Barclays PLC increased its holdings in shares of Royalty Pharma by 16.3% during the 3rd quarter. Barclays PLC now owns 308,887 shares of the biopharmaceutical company's stock worth $8,737,000 after purchasing an additional 43,339 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in Royalty Pharma in the 3rd quarter valued at approximately $61,000. Franklin Resources Inc. lifted its position in shares of Royalty Pharma by 5.0% in the 3rd quarter. Franklin Resources Inc. now owns 1,460,515 shares of the biopharmaceutical company's stock worth $40,705,000 after acquiring an additional 70,130 shares during the period. GAMMA Investing LLC grew its holdings in shares of Royalty Pharma by 31.4% during the 4th quarter. GAMMA Investing LLC now owns 2,471 shares of the biopharmaceutical company's stock worth $63,000 after purchasing an additional 590 shares in the last quarter. Finally, Ridgewood Investments LLC increased its position in shares of Royalty Pharma by 40.8% during the fourth quarter. Ridgewood Investments LLC now owns 30,735 shares of the biopharmaceutical company's stock valued at $784,000 after purchasing an additional 8,913 shares during the period. Institutional investors own 54.35% of the company's stock.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.